Former healthcare association executive selected to lead International Society for Pharmaceutical Engineering.
ISPE—the International Society for Pharmaceutical Engineering announced it has hired John Bournas as president and CEO, succeeding Nancy Berg who announced plans to leave the society last fall. Bournas takes the helm at ISPE with extensive competencies in the healthcare association industry as well as significant international experience and brings to the Society a clear vision for the expansion of its global initiatives and business operations including leveraging technology to extend ISPE’s Membership and educational programs, ISPE reports in a press statement.
"I am certain that with John Bournas’ experience, ISPE is well positioned for continued success," said Damian Greene, Chairman of the ISPE Board of Directors. Greene added, "ISPE has achieved many major milestones during the past few years, including solidifying partnerships with global regulators and spearheading high profile initiatives such as the Drug Shortages Prevention Plan. Under John’s leadership, ISPE will continue to grow these partnerships and initiatives, building on the pharmaceutical industry knowledge and expertise that exists across our 20,000 strong global Membership."
John Bournas is currently CEO/executive director of the World Federation of Hemophilia (WFH) where he led growth of the group’s mission and awareness raising; executed successful corporate affairs partnerships and evolved the group’s digital delivery of educational programs and content. Prior to WFH, he was senior director of International Affairs at the American College of Cardiology; senior director, international at Cardinal Health; and was a former diplomat, with postings in Chile, Australia, and Japan.
"I am pleased to be joining ISPE at a critical time in the pharma and biopharma industry. With companies increasingly challenged to deliver innovative, high-quality medicines within more competitive constraints, Members look to ISPE’s leadership to stimulate dialog on global issues and to capture and share knowledge on implementation of new processes and methods with greater efficiency. I am eager to connect with Members and industry leaders in building collaborative plans that achieve ISPE’s mission and expand its global footprint", said Bournas in the statement.
Bournas earned his MBA at Macquarie University (Australia); MA, Political Science at Fordham University (New York) and BA, International Studies from Fairleigh Dickinson University (New Jersey).
John Bournas takes the helm at ISPE on Sept. 20 and will oversee ISPE’s Annual Meeting, Oct. 12–15, 2014 in Las Vegas, NV, which will coincide with the opening of the ISPE’s office in Washington, DC to establish a permanent executive presence there.
Source: ISPE
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.